{"entity":{"id":"xnw5004","kind":"drug","name":"XNW5004","aka":["EZH2i"],"tldr":"XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.","summary":"XNW5004 is a small-molecule drug developed by Evopoint Biosciences. Its target is EZH2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in follicular lymphoma and prostate cancer. The largest, NCT06702995, plans to enrol 307 participants with primary completion was scheduled for 2026-05-13 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of XNW5004","url":"https://clinicaltrials.gov/search?intr=XNW5004"},{"label":"Sponsor page","url":"https://www.evopointbio.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma","prostate"],"sections":[],"technologies":[],"targets":["ezh2"],"drugs":[],"companies":["evopoint-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07545603","nct07730515","nct06702995","nct06776952"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"Small-molecule drug directed at EZH2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/xnw5004/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/"}],"company":[{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"}],"trial":[{"id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/"},{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/"},{"id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","route":"/trials/nct07545603/"},{"id":"nct06702995","kind":"trial","name":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06702995/"}]}}